Journal of Bioengineering & Biomedical Science

ISSN: 2155-9538

Open Access

Association of recurrent venous thromboembolism and circulating microRNAs


Xiao Wang




Patients with unmerited first venous thromboembolism (VTE) are at a high danger of repeat. Albeit coursing microRNAs (miRNAs) have been seen as related with VTE and are markers of hypercoagulability, this examination is the first to inspect in the case of circling miRNAs are related with the danger of VTE repeat.



A settled case-control study configuration was utilized where plasma tests were acquired from 78 patients with unjustifiable VTE from the Malmö Thrombophilia Study (MATS). An aggregate of 39 VTE patients with intermittent VTE (cases) were coordinated with 39 VTE patients without repetitive VTE (controls) characterized by age and sex (MATS populace). Plasma levels of 179 distinctive miRNAs were assessed in the 78 examples (after anticoagulant treatment was quit) utilizing qPCR. An aggregate of 110 miRNAs were identified in all examples. Among those, 12 miRNAs (miR-15b-5p, miR-106a-5p, miR-197-3p, miR-652-3p, miR-361-5p, miR-222-3p, miR-26b-5p, miR-532-5p, miR-27b-3p, miR-21-5p, miR-103a-3p, and miR-30c-5p) were seen as related with intermittent VTE after numerous rectification test and restrictive calculated relapse examination. A further examination demonstrated that miR-15b-5p, miR-197-3p, miR-27b-3p, and miR-30c-5p showed a pattern after some time, with a bigger distinction in miRNA levels among cases and controls for prior repeat. Of these 12 miRNAs, 8 miRNAs fundamentally corresponded with flowing changing development factor β1/2 (TGFβ1/2). Three of them corresponded with platelet tally.



We have distinguished 12 plasma miRNAs that may can possibly fill in as novel, non-intrusive prescient biomarkers for VTE repeat



Venous thromboembolism (VTE) is the third most normal cardiovascular malady with an expected yearly occurrence pace of 100–200 occasions for every 100,000 people [1,2,3]. The most extreme appearance of VTE is deadly aspiratory embolism (PE) with a yearly occurrence pace of 2–4 occasions for every 100,000 people [4]. VTE is a ceaseless malady with a repeat danger of up to 20% inside 3 years [5]. Intermittent VTE can be deadly in 10–20% of cases [6]. Patients with an unwarranted VTE (without a distinguished major clinical hazard factor, for example, late medical procedure or injury, female hormone treatment or pregnancy, or malignancies) have a higher danger of repeat after stopping of anticoagulation treatment contrasted and those patients with an incited VTE [5, 7]. Long haul anticoagulation treatment, after the underlying VTE, may forestall the repeat however broadened anticoagulation treatment may expand the danger of draining confusions including lethal intracranial discharge [6, 8]. Along these lines, it is critical to distinguish the patients, with a high danger of repeat, who might profit most from ceaseless anticoagulant treatment. There are various distinguished hazard factors identified with intermittent VTE, for example, unjustifiable VTE, raised D-dimer levels, male sex, stoutness, thrombophilia, and family ancestry of VTE [9,10,11,12,13]. There is presently an accord with respect to the ideal term of anticoagulation treatment after a ridiculous VTE occasion. The treatment decision is between a brief term of 3–6 months and an all-encompassing span. Clinical forecast rules have been created to help in this decision yet the capacity of such guidelines to foresee draining gives off an impression of being low [14, 15]. In this way, better novel biomarkers for forecast of repetitive VTE hazard could be of worth.

MicroRNAs (miRNAs) are short, endogenous, and non-coding single-abandoned RNAs that hinder quality articulation by advancing delegate RNA (mRNA) debasement or restraining interpretation [16]. miRNAs have been appeared to assume basic jobs in different organic procedures during advancement and tissue homeostasis by managing the declaration of roughly 90% of every single human quality [17]. Most of miRNAs are communicated intracellularly. Be that as it may, various miRNAs have been distinguished in the extracellular space, including blood and other body liquids [18]. Circling miRNAs can be discharged from cells into the blood in various manners, e.g., encased in exosomes or related with proteins [19, 20]. They are impervious to nuclease assimilation and can be estimated reproducibly, which makes flowing miRNAs appealing as likely biomarkers for maladies. Over the previous decade, circling miRNAs, as expected biomarkers, have been reported in numerous ailments, for example, malignant growth, mental infections, diabetes mellitus, and cardiovascular breakdown [21,22,23,24,25]. Nonetheless, there is just restricted proof on conceivably modified flowing miRNA levels in VTE. As far as anyone is concerned, just a couple of studies have examined the relationship between circling miRNAs and unmerited VTE [25,26,27,28,29]. Wang et al. discovered that miR-424-5p is expanded in patients with intense venous apoplexy and that it is associated with a marker of hypercoagulability (D-dimer and APC-PCI complex) [25]. Up to this point, nonetheless, no outcomes in regards to miRNA articulation in intermittent VTE patients have been accounted for.


The current examination utilized information from an imminent populace based investigation directed in the south of Sweden; Malmö Thrombophilia Study (MATS) [30, 31]. In this investigation, the outflow of plasma miRNAs was estimated in 39 patients with repetitive VTE (cases) and 39 with non-intermittent VTE (controls) fourteen days after cessation of anticoagulation. We theorized that particular miRNAs articulation profile could be utilized to recognize patients at high and generally safe of repeat. In this way, our point was to research the relationship between flowing miRNAs and the danger of VTE repeat.



Patients’ characteristics

Cases were the individuals who were determined to have intermittent VTE during the subsequent period, while controls were those without repetitive VTE. The mean age was 65.3 years for cases and 65.1 years for controls. An aggregate of 67% of the members with intermittent VTE had thrombophilia contrasted and 41% of the members without repetitive VTE (p = 0.09). There was no critical contrast between the two gatherings in weight record (BMI), term of anticoagulant treatment, smoking status, and family ancestry, which was characterized as a past filled with VTE in first-degree family members (kin, child/little girl, or parent).



1. Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT.MicroRNAs are transported in plasma and delivered to recipient cells byhigh-density lipoproteins. Nat Cell Biol. 2011;13(4):423–33.

2. Zampetaki A, Kiechl S, Drozdov I, Willeit P, Mayr U, Prokopi M, et al. PlasmamicroRNA profiling reveals loss of endothelial miR-126 and othermicroRNAs in type 2 diabetes. Circ Res. 2010;107(6):810–7.

3.Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-AgadjanyanEL, et al. Circulating microRNAs as stable blood-based markers for cancerdetection. Proc Natl Acad Sci U S A. 2008;105(30):10513–8.

4.Tijsen AJ, Creemers EE, Moerland PD, de Windt LJ, van der Wal AC, Kok WE,et al. MiR423-5p as a circulating biomarker for heart failure. Circ Res. 2010;106(6):1035–9.

5.Wang X, Sundquist K, Hedelius A, Palmer K, Memon AA, Sundquist J.Circulating microRNA-144-5p is associated with depressive disorders. ClinEpigenetics. 2015;7(1):69.

6.Cieslik J, Mrozinska S, Broniatowska E, Undas A. Altered plasma clotproperties increase the risk of recurrent deep vein thrombosis: a cohortstudy. Blood. 2017

7.Tritschler T, Limacher A, Mean M, Rodondi N, Aujesky D. Usefulness of Ddimertesting in predicting recurrence in elderly patients with unprovokedvenous thromboembolism. Am J Med. 2017;130(10):1221–4.

Note: This work is partly presented in 14th Global Biomarkers SummitOctober18-19,2018 | Amsterdam, Netherlands





Share this article

Google Scholar citation report
Citations: 307

Journal of Bioengineering & Biomedical Science received 307 citations as per Google Scholar report

Journal of Bioengineering & Biomedical Science peer review process verified at publons

Indexed In

arrow_upward arrow_upward